Payment overview · 2025
General Payments
$16,540.84
103 reported records · 25 companies
Healthcare provider profile · identity verified
Pradyumna E Tummala, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · ATLANTA, GA · NPI 1427000959
Verified facts
What the public records show
CMS Open Payments records show Pradyumna E Tummala, MD received $16,540.84 in general payments during 2025 across 103 reported records.
HEARTFLOW, INC. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Ozempic.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $4,449.54 | 26.9% | 2 | 2025 |
| LANTHEUS MEDICAL IMAGING, INC. | Unresolved — no canonical attribution shown | $3,374.80 | 20.4% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $2,091.86 | 12.7% | 14 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,548.93 | 9.4% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,548.37 | 9.4% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,421.49 | 8.6% | 10 | 2025 |
| Ancora Heart, Inc. | Unresolved — no canonical attribution shown | $362.31 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $299.76 | 1.8% | 16 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $171.33 | 1.0% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $160.23 | 1.0% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $147.68 | 0.9% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $134.19 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $114.15 | 0.7% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $110.57 | 0.7% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $107.04 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.32 | 0.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.24 | 0.5% | 4 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $77.79 | 0.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.47 | 0.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.23 | 0.3% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $37.06 | 0.2% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $21.42 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.26 | 0.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.98 | 0.1% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $19.82 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,685.00 | 2 |
| Travel and Lodging | $4,619.42 | 20 |
| Food and Beverage | $4,236.42 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $4,449.54 | 2 | 2025 |
Source payment records
|
|||||
| DEFINITY Normalized: definity |
Drug | LANTHEUS MEDICAL IMAGING, INC. | $3,374.80 | 4 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $1,406.66 | 10 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $1,277.99 | 7 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $914.79 | 6 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $447.52 | 4 | 2025 |
Source payment records
|
|||||
| AccuCinch Normalized: accucinch |
Device | Ancora Heart, Inc. | $362.31 | 1 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $335.82 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $299.76 | 16 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $170.01 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $160.23 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $147.68 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $130.75 | 1 | 2025 |
Source payment records
|
|||||
| PORTICO Normalized: portico |
Device | Abbott Laboratories | $127.75 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $110.57 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $107.04 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $107.04 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $95.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $86.24 | 4 | 2025 |
Source payment records
|
|||||
| ORSIRO MISSION Normalized: orsiro mission |
Device | Teleflex LLC | $77.79 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $69.01 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.23 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $40.89 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $11.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 205 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 50 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 363 | 122 |
| Ezetimibe | Ezetimibe | 342 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 74 |
| Carvedilol | Carvedilol | 233 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 220 | 78 |
| Eliquis | Apixaban | 205 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 194 | 78 |
| Losartan Potassium | Losartan Potassium | 173 | 62 |
| Repatha Sureclick | Evolocumab | 170 | 42 |
| Spironolactone | Spironolactone | 145 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 131 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 38 |
| Xarelto | Rivaroxaban | 103 | 24 |
| Lisinopril | Lisinopril | 81 | 22 |
| Furosemide | Furosemide | 79 | 39 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 65 | 22 |
| Potassium Chloride | Potassium Chloride | 59 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 14 |
| Sotalol | Sotalol Hcl | 55 | 17 |
| Eplerenone | Eplerenone | 49 | 15 |
| Ozempic | Semaglutide | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 17 |
| Amoxicillin | Amoxicillin | 37 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | 14 |
| Nitroglycerin | Nitroglycerin | 33 | 26 |
| Praluent Pen | Alirocumab | 31 | suppressed |
| Repatha Syringe | Evolocumab | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | 11 |
| Atenolol | Atenolol | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16,540.84 · 103 records | HEARTFLOW, INC. | AMVUTTRA, AVVIGO Guidance System, AccuCinch, Attruby, CAMZYOS, COREVALVE EVOLUT R, Cleerly Ischemia, Cleerly Labs, DEFINITY, DRAGONFLY OPSTAR, ELIQUIS, ENTRESTO, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FFRct, FUROSCIX, General - Therapies, Indigo System, Kerendia, LEQVIO, LifeVest, MICRA, NEXLETOL, ORSIRO MISSION, Ozempic, PORTICO, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, TRICLIP, ULTREON, VERQUVO, VYNDAQEL, WATCHMAN FLX, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error